KR102508739B1 - Magl 억제제의 결정형 - Google Patents

Magl 억제제의 결정형 Download PDF

Info

Publication number
KR102508739B1
KR102508739B1 KR1020197017161A KR20197017161A KR102508739B1 KR 102508739 B1 KR102508739 B1 KR 102508739B1 KR 1020197017161 A KR1020197017161 A KR 1020197017161A KR 20197017161 A KR20197017161 A KR 20197017161A KR 102508739 B1 KR102508739 B1 KR 102508739B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
theta
crystalline
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017161A
Other languages
English (en)
Korean (ko)
Other versions
KR20190077561A (ko
Inventor
셰럴 에이 그라이스
토드 케이 존스
커트 지 그림
재클린 로레인 블랭크맨
채닝 로드니 빌스
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20190077561A publication Critical patent/KR20190077561A/ko
Application granted granted Critical
Publication of KR102508739B1 publication Critical patent/KR102508739B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197017161A 2016-11-16 2017-11-15 Magl 억제제의 결정형 Active KR102508739B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Publications (2)

Publication Number Publication Date
KR20190077561A KR20190077561A (ko) 2019-07-03
KR102508739B1 true KR102508739B1 (ko) 2023-03-09

Family

ID=62145805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017161A Active KR102508739B1 (ko) 2016-11-16 2017-11-15 Magl 억제제의 결정형

Country Status (38)

Country Link
US (2) US11142517B2 (https=)
EP (2) EP3541807B1 (https=)
JP (2) JP7042548B2 (https=)
KR (1) KR102508739B1 (https=)
CN (2) CN115093382A (https=)
AU (1) AU2017361257B2 (https=)
BR (1) BR112019010003A2 (https=)
CA (1) CA3043610A1 (https=)
CL (1) CL2019001340A1 (https=)
CO (1) CO2019005045A2 (https=)
CR (1) CR20190242A (https=)
CY (2) CY1124870T1 (https=)
DK (1) DK3541807T3 (https=)
DO (1) DOP2019000120A (https=)
EA (1) EA201991086A1 (https=)
EC (1) ECSP19035171A (https=)
ES (2) ES2900016T3 (https=)
GE (2) GEP20237559B (https=)
HR (2) HRP20211863T1 (https=)
HU (2) HUE064559T2 (https=)
IL (1) IL266548A (https=)
JO (1) JOP20190109B1 (https=)
LT (1) LT3541807T (https=)
MA (2) MA46866B1 (https=)
MX (2) MX389459B (https=)
MY (1) MY199386A (https=)
NI (1) NI201900053A (https=)
PE (1) PE20191239A1 (https=)
PH (1) PH12019501068A1 (https=)
PL (2) PL3964503T3 (https=)
PT (1) PT3541807T (https=)
RS (2) RS62665B1 (https=)
SI (1) SI3541807T1 (https=)
SM (2) SMT202100675T1 (https=)
TN (1) TN2019000151A1 (https=)
UA (1) UA124585C2 (https=)
WO (1) WO2018093953A1 (https=)
ZA (1) ZA201903093B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
GEP20227443B (en) 2018-05-15 2022-11-25 H Lundbeck As Magl inhibitors
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
ES2986417T3 (es) 2018-08-13 2024-11-11 Hoffmann La Roche Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
ES2955037T3 (es) 2018-11-22 2023-11-28 Hoffmann La Roche Nuevos compuestos heterocíclicos
CA3125636A1 (en) * 2019-01-25 2020-07-30 H. Lundbeck A/S Methods of treating disease with magl inhibitors
KR20220101095A (ko) * 2019-11-15 2022-07-19 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
WO2021214550A1 (en) * 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018335A1 (en) 2012-01-06 2015-01-15 Abide Therapeutics, Inc Carbamate compounds and of making and using same
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
HUP0302455A3 (en) 2000-12-18 2005-05-30 Novartis Ag Combination pharmaceutical compositions containing amplodipine and benazepril and their use
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
ATE420644T1 (de) 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
EP2914248B2 (en) 2012-11-02 2023-10-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (en) * 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018335A1 (en) 2012-01-06 2015-01-15 Abide Therapeutics, Inc Carbamate compounds and of making and using same
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Aitipamula et al., Polymorphs, Salts, and Cocrystals: What's in a Name?, 2012, 12, 2147-2152.
Berge et al., Pharmaceutical Salts. Journal of Pharmaceutical Sciences, 1977, 66, 1-19.

Also Published As

Publication number Publication date
WO2018093953A1 (en) 2018-05-24
MA46866B1 (fr) 2021-11-30
EP3541807B1 (en) 2021-09-29
MX389459B (es) 2025-03-20
PT3541807T (pt) 2021-12-09
IL266548A (en) 2019-07-31
RS62665B1 (sr) 2021-12-31
CN110291083A (zh) 2019-09-27
DOP2019000120A (es) 2019-09-30
NZ753241A (en) 2021-06-25
NI201900053A (es) 2019-10-30
JP7350117B2 (ja) 2023-09-25
SMT202100675T1 (it) 2022-01-10
UA124585C2 (uk) 2021-10-13
EP3541807A4 (en) 2020-04-22
EP3964503B1 (en) 2023-11-08
KR20190077561A (ko) 2019-07-03
MX2019005767A (es) 2019-12-05
LT3541807T (lt) 2021-12-27
CN110291083B (zh) 2022-06-17
US20200190063A1 (en) 2020-06-18
MA46866A (fr) 2021-06-02
JP2019537596A (ja) 2019-12-26
CL2019001340A1 (es) 2019-10-04
ES2900016T3 (es) 2022-03-15
AU2017361257A1 (en) 2019-05-30
PL3964503T3 (pl) 2024-04-02
BR112019010003A2 (pt) 2019-08-20
CR20190242A (es) 2019-07-09
RS65016B1 (sr) 2024-01-31
CY1126586T1 (el) 2026-02-25
US11142517B2 (en) 2021-10-12
HUE056973T2 (hu) 2022-04-28
EP3541807A1 (en) 2019-09-25
JOP20190109A1 (ar) 2019-05-09
US20220235037A1 (en) 2022-07-28
GEP20237559B (en) 2023-10-25
TN2019000151A1 (en) 2020-10-05
SMT202300494T1 (it) 2024-01-10
EP3964503A1 (en) 2022-03-09
JP2022084717A (ja) 2022-06-07
ZA201903093B (en) 2020-11-25
GEAP202315091A (en) 2023-05-10
JP7042548B2 (ja) 2022-03-28
HUE064559T2 (hu) 2024-03-28
HRP20211863T1 (hr) 2022-03-04
SI3541807T1 (sl) 2022-01-31
CY1124870T1 (el) 2022-11-25
RU2019116689A3 (https=) 2021-02-26
US11993588B2 (en) 2024-05-28
MA58133B1 (fr) 2024-02-29
EA201991086A1 (ru) 2019-11-29
DK3541807T3 (da) 2021-12-06
HRP20231697T1 (hr) 2024-03-15
JOP20190109B1 (ar) 2022-09-15
AU2017361257B2 (en) 2022-02-10
RU2019116689A (ru) 2020-12-17
ECSP19035171A (es) 2019-05-31
PE20191239A1 (es) 2019-09-16
CO2019005045A2 (es) 2019-05-31
ES2966939T3 (es) 2024-04-25
MY199386A (en) 2023-10-25
PL3541807T3 (pl) 2022-01-17
MX2022000249A (es) 2022-02-03
CA3043610A1 (en) 2018-05-24
PH12019501068A1 (en) 2019-08-19
CN115093382A (zh) 2022-09-23
EP3964503C0 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
KR102508739B1 (ko) Magl 억제제의 결정형
TWI727949B (zh) 調節蛋白質激酶之化合物的固態形式
US12551474B2 (en) Use of pridopidine for the treatment of fragile X syndrome
US20220002292A1 (en) Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator
BR112021010720A2 (pt) Métodos para tratar ou prevenir gota ou hiperuricemia
KR20080091132A (ko) 지방산 아미드 가수분해 효소의 억제제
US12415790B2 (en) GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40069310A (en) A crystalline form of a magl inhibitor
HK40069310B (en) A crystalline form of a magl inhibitor
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
EA041551B1 (ru) Кристаллические формы ингибитора magl
HK40009165B (en) A crystalline form of a magl inhibitor
HK40009165A (en) A crystalline form of a magl inhibitor
NZ753241B2 (en) Crystalline forms of a magl inhibitor
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
WO2017073738A1 (ja) フェキソフェナジンを有効成分とする錠剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201112

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220503

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220801

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230210

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230307

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230307

End annual number: 3

Start annual number: 1

PG1601 Publication of registration